Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRYAB | P02511 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | USP2 | O75604 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | FNTA | P49354 | 1/20 | 0.55 |
| ▸ | FNTB | P49356 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.54 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.54 |
| ▸ | CRYAA | P02489 | 1/20 | 0.52 |
| ▸ | PTGES | O14684 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11660729 | 0.85 | MAPT (0.78) | CRYABMAPTUSP2ALDH1A1CYP3A4 | |
| SCHEMBL16249832 | 0.85 | MAPT (0.78) | CRYABMAPTUSP2ALDH1A1CYP3A4 | |
| SCHEMBL31378752 | 0.85 | MAPT (0.78) | CRYABMAPTUSP2ALDH1A1CYP3A4 | |
| SCHEMBL30272447 | 0.85 | MAPT (0.78) | CRYABMAPTUSP2ALDH1A1CYP3A4 | |
| SCHEMBL2370125 | 0.85 | MAPT (0.78) | CRYABMAPTUSP2ALDH1A1CYP3A4 | |
| SCHEMBL30187473 | 0.83 | CRYAB (0.57) | CRYABMAPTUSP2ALDH1A1CYP3A4 | |
| SCHEMBL30516927 | 0.83 | CRYAB (0.56) | CRYABMAPTUSP2ALDH1A1CYP3A4 | |
| SCHEMBL30531015 | 0.82 | CRYAB (0.75) | CRYABMAPTUSP2ALDH1A1CYP3A4 | |
| SCHEMBL30531014 | 0.82 | CRYAB (0.75) | CRYABMAPTUSP2ALDH1A1CYP3A4 | |
| SCHEMBL30516911 | 0.80 | CRYAB (0.55) | CRYABMAPTUSP2ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11313866-B2 | Method of diagnosing and treating asphyxia | INFANDX AG (DE) | 2022-04-26 | — | — | US | claimed |
| US-10514383-B2 | Diagnosis and treatment of neonatal encephalopathy | INFANDX AG (DE) | 2019-12-24 | — | — | US | claimed |
| US-20140308687-A1 | Method and Use of Metabolites for the Diagnosis and Differentiation of Neonatal Encephalopathy | INFANDX AG (DE) | 2014-10-16 | — | — | US | claimed |
| EP-2771696-A2 | METHOD AND USE OF METABOLITES FOR THE DIAGNOSIS AND DIFFERENTIATION OF NEONATAL ENCEPHALOPATHY | InfanDx AG (DE) | 2014-09-03 | — | — | EP | claimed |
| WO-2013060788-A2 | METHOD AND USE OF METABOLITES FOR THE DIAGNOSIS AND DIFFERENTIATION OF NEONATAL ENCEPHALOPATHY | INFANDX AG (DE) | 2013-05-02 | — | — | WO | claimed |
| EP-2587264-A1 | Method and use of metabolites for the diagnosis and differentiation of neonatal encephalopathy | InfanDx AG (DE) | 2013-05-01 | — | — | EP | claimed |
| CN-114127306-B | Lipid modified oligonucleotides and methods of use thereof | 加利福尼亚大学董事会 | 2025-04-15 | — | — | CN | disclosed |
| US-20240425932-A1 | LIPID-MODIFIED OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-26 | — | — | US | disclosed |
| US-12077826-B2 | Lipid-modified oligonucleotides and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-09-03 | — | — | US | disclosed |
| EP-2771696-B1 | METHODS MAKING USE OF PANELS OF METABOLITES FOR THE DIAGNOSIS AND DIFFERENTIATION OF NEONATAL ENCEPHALOPATHY | INFANDX AG (DE) | 2022-09-14 | — | — | EP | disclosed |
| US-20220275438-A1 | LIPID-MODIFIED OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | DEFENSE ADVANCED RESEARCH PROJECTS AGENCY | 2022-09-01 | — | — | US | disclosed |
| EP-2953604-B1 | COSMETIC COMPOSITION | UNILEVER GLOBAL IP LTD (GB) | 2022-06-22 | — | — | EP | disclosed |
| EP-3997237-A1 | LIPID-MODIFIED OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | The Regents of the University of California (US) | 2022-05-18 | — | — | EP | disclosed |
| WO-2011012553-A1 | METHOD FOR PREDICTING THE LIKELIHOOD OF AN ONSET OF AN INFLAMMATION ASSOCIATED ORGAN FAILURE | BIOCRATES LIFE SCIENCES AG (AT) | 2011-02-03 | — | — | WO | disclosed |
| EP-2219587-A1 | STEROL-MODIFIED AMPHIPHILIC LIPIDS | The Regents of the University of California (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009064696-A1 | STEROL-MODIFIED AMPHIPHILIC LIPIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20020148006-A1 | Transgenic plants with modified sterol compositions | ASGROW SEED COMPANY, L.L.C. | 2002-10-10 | — | — | US | disclosed |
| EP-0958370-A1 | TRANSGENIC PLANTS WITH MODIFIED STEROL BIOSYNTHETIC PATHWAYS | MONSANTO COMPANY (US) | 1999-11-24 | — | — | EP | disclosed |
| WO-1998045457-A1 | TRANSGENIC PLANTS WITH MODIFIED STEROL BIOSYNTHETIC PATHWAYS | MONSANTO COMPANY (US) | 1998-10-15 | — | — | WO | disclosed |
| EP-0166542-B1 | TRITERPENYL ESTERS OF ORGANIC ACIDS, PROCESS FOR THEIR PRODUCTION, AND HYPOLIPIDEMIC AGENTS COMPOSED OF THEM | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1990-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020148006-A1 | Transgenic plants with modified sterol compositions | SREBF1, SREBF2, ERG28 | CRYAB 2454/4885MAPT 3312/4885USP2 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.